Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoniazid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | MPO | P05164 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoniazid SCHEMBL20771838 | 0.92 | KDM4E (0.54) | KDM4EADORA3CYP1A2CYP2C19MPO | |
| Pyrazinamide SCHEMBL21903116 | 0.84 | ADORA3 (0.72) | KDM4EADORA3TSHRMC4RADRA1A | |
| Pyrazinamide SCHEMBL30729501 | 0.82 | ADORA3 (0.95) | KDM4EADORA3TSHRMC4RADRA1A | |
| Isoniazid SCHEMBL7061582 | 0.81 | KDM4E (0.68) | KDM4EADORA3CYP1A2CYP2C19MPO | |
| Isoniazid SCHEMBL7744265 | 0.80 | KDM4E (0.91) | KDM4EADORA3CYP1A2CYP2C19MPO | |
| Isoniazid SCHEMBL16642161 | 0.80 | KDM4E (1.00) | KDM4EADORA3CYP1A2CYP2C19MPO | |
| Pyrazinamide SCHEMBL18364991 | 0.80 | — | — | |
| Pyrazinamide SCHEMBL18364989 | 0.80 | — | — | |
| Isoniazid SCHEMBL228 | 0.80 | KDM4E (1.00) | KDM4EADORA3CYP1A2CYP2C19MPO | |
| Isoniazid SCHEMBL12264083 | 0.80 | KDM4E (1.00) | KDM4EADORA3CYP1A2CYP2C19MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102920707-A | Process for preparing compound antituberculous preparation | UNIV SHENYANG PHARMACEUTICAL | 2013-02-13 | — | — | CN | claimed |
| CN-1390546-A | Prescription of compound rifampin | GAO HUA (CN) | 2003-01-15 | — | — | CN | claimed |
| WO-2026107393-A2 | AAV CAPSID MODIFICATIONS THAT REDUCE IMMUNOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12618082-B2 | Engineered muscle targeting compositions | THE BROAD INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4714496-A2 | TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | OrfoNeuro ApS (DK) | 2026-03-25 | — | — | EP | disclosed |
| US-20260076361-A1 | BLOOD PRESERVATION COMPOSITIONS, DEVICES, AND USES THEREOF | EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709357-A2 | EXTRACELLULAR VESICLE COMPOSITIONS AND PREPARATION | Virginia Tech Intellectual Properties, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-17 | — | — | US | disclosed |
| CN-102727496-A | Compound antituberculosis drug oral solid preparation and its preparation method | SHANGHAI SHUANGJIAN MODERN PHARMACEUTICAL TECHNOLOGY CONSULTING CO LTD | 2012-10-17 | — | — | CN | disclosed |
| EP-2370043-A1 | METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS | Apotex Technologies Inc. (CA) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010063114-A1 | METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS | APOTEX TECHNOLOGIES INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| CN-101601641-A | A kind of medical solid compound preparation and preparation method thereof | CHONGQING HUAPONT PHARM CO LTD (CN) | 2009-12-16 | — | — | CN | disclosed |
| US-20080138452-A1 | Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs | JOHRI RAKESH KAMAL | 2008-06-12 | — | — | US | disclosed |
| US-20060121138-A1 | Hepatocurative effect of Emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs | JOHRI RAKESH K | 2006-06-08 | — | — | US | disclosed |
| US-7001619-B2 | Particularly effective against hepatotoxicity caused by anti-TB drugs, such as Rifampicin, Pyrazinamide, and isoniazid. | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-02-21 | — | — | US | disclosed |
| CN-1627955-A | Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytoch rome P-45O | COUNCIL SCIENT IND RES (IN) | 2005-06-15 | — | — | CN | disclosed |
| US-20030185922-A1 | Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618082-B2 | Engineered muscle targeting compositions | MUSK, MYO3B, MYOF | KDM4E 1369/4885ADORA3 3168/4885CYP1A2 2375/4885 |
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | LGALS1, LGALS3BP, LGALS3 | KDM4E 2556/4885ADORA3 2900/4885CYP1A2 4831/4885 |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | RNMT, NSUN2, FBL | KDM4E 1820/4885ADORA3 2054/4885CYP1A2 4679/4885 |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | MICA, PDCD1LG2, TLR9 | KDM4E 4172/4885ADORA3 1847/4885CYP1A2 4882/4885 |
| US-20260076361-A1 | BLOOD PRESERVATION COMPOSITIONS, DEVICES, AND USES THEREOF | CD47, SELP, CD63 | KDM4E 3105/4885ADORA3 3401/4885CYP1A2 4098/4885 |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | FLNB, FLNA, DAGLB | KDM4E 3599/4885ADORA3 2516/4885CYP1A2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.